Today, Selick didn't say a word about phase I .
I guess he's already preparing some data by ASCO and he doesn't want to say nothing before that date.
And when he is asked by "interim data"?
Did you realized that he answers quickly and brief? Very concise.
In fact, he doesn't provide any information.
The English MC was really hyping Abraxane and Celgene's marketing machine. In the end as Selick said at the conference , it's all about the numbers. TH-302 shows much better efficacy , and safety.
Sentiment: Strong Buy
Have you read the last Merck Conference Call ??
"Event" Futility Analysis
"Indication" Soft tissue sarcoma
have you check the FDA Calendar?
The date for interim data for sarcoma by 30th June IS GONE.
Something is going on here, something BIG.